UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.Date of Report: October 27, 2005
(Date of earliest event reported)
Theravance, Inc.
(Exact name of registrant as specified in its charter)
DE
(State or other jurisdiction
of incorporation) 0-30319
(Commission File Number) 94-3265960
(IRS Employer
Identification Number)
901 Gateway Boulevard, South San Francisco, CA
(Address of principal executive offices) 94080
(Zip Code)
650-808-6000
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 9.01. Financial Statements and Exhibits
(c) Exhibits.
99.1 Press Release of Theravance, Inc. dated October 27, 2005 regarding its financial results for the quarter ended September 30, 2005, furnished in accordance with Item 2.02 of this Current Report on Form 8-K.
99.1 Press Release of Theravance, Inc. dated October 27, 2005
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 27, 2005
THERAVANCE, INC.
By: /s/ Michael W. Aguiar
Michael W. Aguiar
Senior Vice President and Chief Financial Officer